The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
In this video, Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, shares insights into advancements that have been made in multiple myeloma treatment. Dr Ocio comments on the potential of integrating novel agents, including CELMoDs, bispecifics, and CAR T-cells, in the newly diagnosed setting. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
